Where is psilocybin legal?
The 2026 treatment map
Oregon and Colorado run licensed psilocybin programs, and New Mexico's law gives its health department until Dec 31, 2027 to start a medical one. Federal law keeps psilocybin in Schedule I. Abroad, we state a country's law only where we've read it in a statute, regulator or gazette page, eight countries so far, and everywhere else this page says we haven't checked. Each line of law below links its source and the day it was checked. The counts come from the 2,465 treatment sites and 1,604 registered studies in the index.
The two licensed states
Service centers with an active OHA license
Adults 21+ may buy and consume psilocybin only during a supervised session at an OHA-licensed service center (ORS 475A); no prescription is required. (source, as of Oct 4, 2026)
We hold 28 Oregon psilocybin records. 21 are on OHA's register of licensees, read Nov 16, 2026. The other 7 aren't, though some call themselves licensed in a directory or on their own site. The register lists only licensees who agreed to appear in it, and we count what it shows.
The Oregon list →Healing centers approved on the register
Adults 21+ may receive psilocybin or psilocyn services from a licensed facilitator at a state-licensed healing center under the Natural Medicine Health Act (C.R.S. 12-170). (source, as of Oct 4, 2026)
The state register also lists 5 applications as pending and 5 licenses as surrendered. We print its status word beside every number.
The Colorado list →Federal law, and the trials
Psilocybin and psilocyn are Schedule I controlled substances under federal law (21 CFR 1308.11(d)). (source, as of Oct 4, 2026) Then there are the registered trials: we count 322 US sites recruiting right now, across 41 states, and 581 worldwide. Every one links to its ClinicalTrials.gov registration, which says what the study tests and who can join.
Outside the US
These are the countries whose law on these medicines we've read at the source. Each line is quoted as written, with the page it comes from and the day it was checked; the last column counts the retreats and clinics we hold there.
| Country | What the law says | Records |
|---|---|---|
| Canada | Psilocybin is controlled in Canada; Health Canada allows access only through authorized clinical trials, Special Access Program requests by practitioners, or case-by-case s.56(1) exemptions. (source, as of Oct 4, 2026) MDMA is a restricted drug in Canada; practitioners may request it case by case through Health Canada's Special Access Program for serious or life-threatening conditions when other treatments fail. (source, as of Oct 4, 2026) | 63 |
| Czech Republic | Since 1 Jan 2026, specialist doctors may prescribe and give compounded psilocybin for severe or cancer-related depression after standard treatment fails, under dose and supervision limits. (source, as of Oct 4, 2026) | 3 |
| Germany | BfArM lists a confirmed compassionate-use (hardship) program for psilocybin in treatment-resistant depression, run by ZI Mannheim and valid until 17 June 2027. (source, as of Oct 4, 2026) | 9 |
| Mexico | Psilocybin and hallucinogenic mushrooms are controlled (General Health Law art. 245); possession for recognized Indigenous or Afro-Mexican community ceremonies is not prosecuted (CPF art. 195 bis). (source, as of Oct 4, 2026) Ibogaine is not on the controlled-substance lists of Mexico's General Health Law (arts. 234 and 245, as amended to January 2026). (source, as of Oct 4, 2026) | 46 |
| Netherlands | Psilocybin (Opium Act List I) and psilocybin mushrooms (List II) are controlled; truffles (sclerotia) are not listed, and the government has called them legal products (2011). (source, as of Oct 4, 2026) | 45 |
| New Zealand | Medsafe can approve individual practitioners under reg. 22 of the Misuse of Drugs Regulations 1977 to prescribe, supply and administer psychedelics such as psilocybin outside research. (source, as of Oct 4, 2026) | 6 |
| Switzerland | FOPH may grant a treating doctor a per-patient exceptional licence for limited medical use of psilocybin, a banned narcotic, when other therapies are exhausted (Art. 8(5) NarcA). (source, as of Oct 4, 2026) FOPH may grant a treating doctor a per-patient exceptional licence for limited medical use of LSD, a banned narcotic, when other therapies are exhausted (Art. 8(5) NarcA). (source, as of Oct 4, 2026) FOPH may grant a treating doctor a per-patient exceptional licence for limited medical use of MDMA, a banned narcotic, when other therapies are exhausted (Art. 8(5) NarcA). (source, as of Oct 4, 2026) | 10 |
| The Bahamas | Psilocybine and psilocine are listed in the Dangerous Drugs Act (Application) Order 1994, which applies Part IV of the Dangerous Drugs Act (Ch. 228) to them. (source, as of Oct 4, 2026) | 4 |
Not checked yet: Jamaica (34 records), Australia (27), Peru (17), Costa Rica (15), Portugal (9), Spain (7), Israel (6), Brazil (4), Colombia (2), Ecuador (2), France (1), Gabon (1) and Malta (1). We haven't verified these countries' law against a primary source, so this page makes no claim about it either way. Their retreat listings describe themselves: a listing with nothing else behind it carries the index's “directory claim” label, and an operator's own legal claim is printed as the operator's. Check local law before you book.
And the other psychedelic medicines?
Different compounds sit under different rules. What the clinics in the index give:
Ketamine and esketamine account for most of the 2,248 clinics we track. US federal law on each medicine, line by line:
| Medicine | US federal law |
|---|---|
| ketamine | Ketamine is Schedule III (21 CFR 1308.13(c)) and FDA-labeled for anesthesia; psychiatric use is off-label, which FDA says prescribers generally may do when medically appropriate. (source, as of Oct 4, 2026) |
| esketamine | Spravato (esketamine) is FDA-approved for adults with treatment-resistant depression; its REMS limits use to certified healthcare settings with at least 2 hours of monitoring. (source, as of Oct 4, 2026) |
| MDMA | MDMA is a Schedule I controlled substance under federal law (21 CFR 1308.11(d)). (source, as of Oct 4, 2026) |
| LSD | LSD is a Schedule I controlled substance under federal law (21 CFR 1308.11(d)). (source, as of Oct 4, 2026) |
| DMT | DMT is a Schedule I controlled substance under federal law (21 CFR 1308.11(d)). (source, as of Oct 4, 2026) |
| ibogaine | Ibogaine is a Schedule I controlled substance under federal law (21 CFR 1308.11(d)). (source, as of Oct 4, 2026) |
| mescaline | Mescaline and peyote are Schedule I controlled substances under federal law (21 CFR 1308.11(d)). (source, as of Oct 4, 2026) |
Ibogaine outside the US: see Mexico in the table above. A record's own basis line, where it has one, is what that operator cites, and the record says whose words it is.